Balchem Corporation
NASDAQ•BCPC
CEO: Mr. Theodore L. Harris
セクター: Basic Materials
業種: Chemicals - Specialty
上場日: 1986-06-03
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
連絡先情報
時価総額
$5.47B
PER (TTM)
35.3
33.7
配当利回り
0.6%
52週高値
$183.90
52週安値
$139.17
52週レンジ
順位21Top 7.6%
6.0
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$263.62M+0.00%
直近4四半期の推移
EPS
$1.22+0.00%
直近4四半期の推移
フリーCF
$94.55M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Total Sales Increased 8.8% Net sales totaled $1.04B in 2025, reflecting 8.8% growth driven by all segments compared to 2024 results.
Net Earnings Grew 20.5% Net earnings reached $154.85M, showing strong 20.5% improvement driven by margin expansion and higher sales volume.
Operating Margin Expanded to 20.2% Operating margin improved to 20.2% of net sales, up from 19.2% in 2024, reflecting better cost control across operations.
Human Nutrition Sales Up 9.9% HNH segment sales grew 9.9% to $659.39M, contributing significantly to overall company revenue growth for the fiscal year.
リスク要因
Raw Material Shortages Risk Reliance on global sourcing subjects sales and operations to supply chain disruptions and inflationary cost pressures impacting margins.
Ethylene Oxide Regulatory Headwinds EPA Interim Decision on EtO use limits applications and imposes mitigation measures, potentially increasing customer costs and limiting sales.
Intense Market Competition Risks Competition in animal feed and supplement markets is highly price sensitive, potentially limiting pricing power and margin maintenance.
Evolving Cybersecurity Threat Landscape Continuous, evolving cybersecurity attacks, including AI-driven methods, pose risks to systems, data integrity, and operational continuity.
見通し
Capital Expenditures Projected 2026 Capital expenditures projected between $40.00M and $45.00M for 2026, supporting growth and efficiency projects across facilities.
Drive Efficiency and Differentiation Strategy focuses on leveraging scientific data for human nutrition differentiation and driving production efficiencies in commodity markets.
Active Pursuit of Acquisitions Expect operations to generate sufficient cash flow to fund working capital, investments, and actively pursue additional acquisition candidates.
同業比較
売上高 (TTM)
$27.95B
$9.54B
$5.12B
粗利益率 (最新四半期)
59.9%
49.3%
46.2%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| ESI | $7.55B | 39.3 | 7.3% | 31.9% |
| EGO | $7.30B | 14.4 | 12.4% | 19.3% |
| SSL | $7.21B | 51.8 | 1.6% | 36.9% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.7%
緩やかな成長
4四半期純利益CAGR
1.9%
収益性の緩やかな改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年4月22日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし